The drug given orphan drug status is most definately their folate targeting ADC 853, which is wholly owned by Immunogen. Is it that much effort to put out your own press release? At this point even this board of directors has to be getting tired of this #$%$. Junius should just resign or kill himself. I never thought this company would still be floundering in 2014 with such an impressive technology at their disposal. I wonder what those 10 or so biz development people do with their time. This is just hard to watch anymore.
Giving them the benefit of the doubt here -- cuz it's easy to do press releases -- but would there be any situation (like in negotiations tied to the stock price) that would prevent them from issuing a PR?
To be honest I called investor relations, got voicemail, but left a nasty message telling them that I think they are a bunch of bozos and mishandling their PR, doing nothing to promote themselves and assuage investors despite a near 45% price drop in 6 months. Furthermore, I informed them I have reduced my share number by ~90% given my lack of confidence in their management.
maybe they don't want to raise expectations before new exec options are priced, or they don't need to sell any insider shares right now? Let Dan know how you feel, he really cares about shareholder opinion.